Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of primary glioblastoma multiforme with cetuximab [Erbitux; Merck KGaA], radiotherapy and temozolomide (GERT) - phase I/II trial.

Trial Profile

Treatment of primary glioblastoma multiforme with cetuximab [Erbitux; Merck KGaA], radiotherapy and temozolomide (GERT) - phase I/II trial.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Cetuximab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Acronyms GERT
  • Most Recent Events

    • 12 Jul 2011 Planned end date (Feb 2010) added as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-003911-63).
    • 08 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top